Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have launched an innovative preventive care model in Latin America, focusing on diabetic patients. The model provides free retinal risk screenings at local pharmacies, shifting care from hospitals to convenient locations.
The initiative integrates key healthcare stakeholders including pharmacy chains, health clinics, insurance companies, and pharmaceutical partners. Ainnova's AI platform identifies at-risk patients before symptoms appear, enabling early intervention and better clinical outcomes.
Through Ai-Nova Acquisition Corp. (AAC), the companies hold worldwide licensing rights for Ainnova's technology portfolio. The company projects significant revenue growth for 2025 and 2026 as commercial agreements and pilot programs expand across multiple countries.
Avant Technologies (OTCQB: AVAI) e il suo partner in joint venture Ainnova Tech hanno lanciato un modello innovativo di prevenzione sanitaria in America Latina, rivolto ai pazienti diabetici. Il modello offre screening gratuiti del rischio retinico presso le farmacie locali, spostando l'assistenza dagli ospedali a luoghi più accessibili.
L'iniziativa coinvolge importanti attori del settore sanitario, tra cui catene di farmacie, cliniche, compagnie assicurative e partner farmaceutici. La piattaforma AI di Ainnova individua i pazienti a rischio prima della comparsa dei sintomi, permettendo un intervento precoce e migliori risultati clinici.
Attraverso Ai-Nova Acquisition Corp. (AAC), le aziende detengono i diritti di licenza mondiali per il portafoglio tecnologico di Ainnova. L'azienda prevede una crescita significativa dei ricavi per il 2025 e il 2026, grazie all'espansione di accordi commerciali e programmi pilota in diversi paesi.
Avant Technologies (OTCQB: AVAI) y su socio en empresa conjunta Ainnova Tech han lanzado un modelo innovador de cuidado preventivo en América Latina, enfocado en pacientes diabéticos. El modelo ofrece exámenes gratuitos de riesgo retiniano en farmacias locales, trasladando la atención de los hospitales a ubicaciones más accesibles.
La iniciativa integra a los principales actores del sector salud, incluyendo cadenas de farmacias, clínicas, compañías de seguros y socios farmacéuticos. La plataforma de IA de Ainnova identifica a pacientes en riesgo antes de que aparezcan los síntomas, permitiendo una intervención temprana y mejores resultados clínicos.
A través de Ai-Nova Acquisition Corp. (AAC), las empresas poseen los derechos de licencia mundial para el portafolio tecnológico de Ainnova. La compañía proyecta un crecimiento significativo en ingresos para 2025 y 2026, a medida que se expanden acuerdos comerciales y programas piloto en varios países.
Avant Technologies (OTCQB: AVAI)와 합작 파트너 Ainnova Tech가 라틴 아메리카에서 당뇨병 환자에 중점을 둔 혁신적인 예방 관리 모델을 출시했습니다. 이 모델은 지역 약국에서 무료 망막 위험 검사를 제공하여 병원에서 편리한 장소로 의료 서비스를 전환합니다.
이 이니셔티브는 약국 체인, 건강 클리닉, 보험사 및 제약 파트너 등 주요 의료 관계자들을 통합합니다. Ainnova의 AI 플랫폼은 증상이 나타나기 전에 위험 환자를 식별하여 조기 개입과 더 나은 임상 결과를 가능하게 합니다.
Ai-Nova Acquisition Corp. (AAC)를 통해 두 회사는 Ainnova의 기술 포트폴리오에 대한 전 세계 라이선스 권리를 보유하고 있습니다. 회사는 여러 국가에서 상업 계약과 파일럿 프로그램이 확대됨에 따라 2025년과 2026년에 상당한 매출 성장을 예상하고 있습니다.
Avant Technologies (OTCQB : AVAI) et son partenaire en coentreprise Ainnova Tech ont lancé un modèle innovant de soins préventifs en Amérique latine, ciblant les patients diabétiques. Ce modèle propose des dépistages gratuits des risques rétiniens dans les pharmacies locales, déplaçant les soins des hôpitaux vers des lieux plus accessibles.
L’initiative intègre les principaux acteurs de la santé, notamment les chaînes de pharmacies, les cliniques, les compagnies d’assurance et les partenaires pharmaceutiques. La plateforme IA d’Ainnova identifie les patients à risque avant l’apparition des symptômes, permettant une intervention précoce et de meilleurs résultats cliniques.
Grâce à Ai-Nova Acquisition Corp. (AAC), les entreprises détiennent les droits de licence mondiaux sur le portefeuille technologique d’Ainnova. La société prévoit une croissance significative de ses revenus pour 2025 et 2026, à mesure que les accords commerciaux et les programmes pilotes se développent dans plusieurs pays.
Avant Technologies (OTCQB: AVAI) und sein Joint-Venture-Partner Ainnova Tech haben ein innovatives Präventionsmodell in Lateinamerika gestartet, das sich auf Diabetiker konzentriert. Das Modell bietet kostenlose Netzhautriskoscreenings in lokalen Apotheken an und verlagert die Versorgung von Krankenhäusern zu bequemeren Standorten.
Die Initiative integriert wichtige Akteure im Gesundheitswesen, darunter Apothekenketten, Gesundheitskliniken, Versicherungen und pharmazeutische Partner. Die KI-Plattform von Ainnova erkennt Risikopatienten, bevor Symptome auftreten, und ermöglicht so frühzeitige Interventionen und bessere klinische Ergebnisse.
Über Ai-Nova Acquisition Corp. (AAC) besitzen die Unternehmen weltweite Lizenzrechte an Ainnovas Technologieportfolio. Das Unternehmen prognostiziert für 2025 und 2026 ein erhebliches Umsatzwachstum, da kommerzielle Vereinbarungen und Pilotprogramme in mehreren Ländern ausgeweitet werden.
- Strategic partnership providing worldwide licensing rights for Ainnova's AI technology portfolio
- Projected explosive revenue growth for 2025 and 2026
- Commercial agreements and pilot programs already established in multiple countries
- Cost-free preventive care model eliminating barriers to early diagnosis
- Integration of multiple healthcare stakeholders creating a sustainable business model
- Operating in emerging markets which may present regulatory and implementation challenges
- Early stage of commercial deployment with unproven revenue projections
- Dependency on multiple stakeholders for successful implementation
At the heart of this model is a seamless experience for diabetic patients, who can now receive free retinal risk screenings at their neighborhood pharmacies, which will eliminate the barriers to an early diagnosis. This approach moves care out of the hospital and into every day, high-traffic locations—bringing timely early disease detection to the patient at a point of convenience.
Avant's partner, Ainnova, is spearheading this model across
This breakthrough is addressing one of the biggest challenges in chronic care: many patients, especially those with diabetes, lack awareness of the risks associated with their condition and do not seek specialist care until complications are advanced. Ainnova's solution is changing the industry—identifying risk before symptoms appear, and doing so in a way that is frictionless for the patient. By activating those with the strongest incentive to intervene early, Ainnova has found a sustainable, scalable formula for delivering high-value preventive care—at no cost to the patient—and unlocking powerful new lines of collaboration across the industry.
With commercial agreements and pilot programs underway in several countries, the company is forecasting explosive revenue growth and a greater reach in both 2025 and 2026.
The launch of this preventive care model and the growth of Ainnova's revenue and reach is significant to Avant because the two companies formed Ai-Nova Acquisition Corp. (AAC) to develop and market Ainnova's technology portfolio, which includes its AI platform. AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include
About Ainnova Tech, Inc.
Ainnova is a
About Avant Technologies, Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc. info@avanttechnologies.com
Logo: https://mma.prnewswire.com/media/2370694/5404726/Avant_Technologies.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-partner-ainnova-launch-transformative-preventative-care-model-for-chronic-patients-across-latin-america-302500064.html
SOURCE Avant Technologies Inc.
FAQ
What is the partnership between Avant Technologies (AVAI) and Ainnova Tech?
How does AVAI's new preventive care model work in Latin America?
What is the revenue outlook for Avant Technologies' (AVAI) new healthcare initiative?
Who are the key stakeholders in AVAI's Latin American healthcare model?
What problem does Avant Technologies' (AVAI) new healthcare model solve?
